Eikelenboom M J, Uitdehaag B M J, Petzold A
Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Mult Scler Int. 2011;2011:823176. doi: 10.1155/2011/823176. Epub 2011 Apr 14.
Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed. Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH). Methods. An exploratory cross-sectional (n = 51) and longitudinal (n = 34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup. Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2, P < .0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P < .05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS 2, P < .05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS 2, P < .05). Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results.
背景。多发性硬化症(MS)中的残疾与神经轴突退变有关。需要一种可靠的用于神经轴突退变的血液生物标志物。目的。探讨脑脊液(CSF)与神经轴突退变的一种蛋白质生物标志物——神经丝重链(NfH)的血清浓度之间的关系。方法。对MS患者的脑脊液(CSF)和血清NfH磷酸化形式水平进行一项探索性横断面研究(n = 51)和纵向研究(n = 34)。在基线时对扩展残疾状态量表(EDSS)、CSF以及NfH - SMI34和NfH - SMI35的血清水平进行定量。在3年随访时评估残疾进展情况。结果。在基线时,与复发缓解型MS(RRMS,EDSS 2)患者相比,原发性进展型MS(PPMS,EDSS 6)和继发性进展型MS(SPMS,EDSS 6)患者的残疾程度更高(P <.0001)。血清和CSF NfH磷酸化形式水平不相关。PPMS患者(2.05 ng/mL)的NfH - SMI34基线血清水平显著高于SPMS患者(0.03 ng/mL)和RRMS患者(1.56 ng/mL)(P <.05)。在SPMS中,血清NfH - SMI34水平高于CSF水平预示着从基线开始的残疾进展(ΔEDSS≥2,P <.05)。在RRMS中,CSF NfH - SMI35水平高于血清水平预示着残疾进展(ΔEDSS≥2,P <.05)。结论。在MS中,血清和CSF NfH - SMI34和NfH - SMI35水平彼此不相关。CSF和血清NfH水平的定量关系表明,中枢神经系统的神经轴突退变可能是RRMS中残疾进展的原因。在残疾程度更严重的PP/SPMS患者中,不能排除外周神经系统的细微病变作为血液NfH水平的另一个来源。因此,在中枢神经系统(CNS)疾病中对血液蛋白质生物标志物数据的解释应考虑外周神经系统(PNS)病变可能影响结果的可能性。